Subtype
Anorectal Neoplasm
CI-CAN-00001814Explore in graph →
Non-malignant504 active trials1 approved drugs6 evidence items
- NCIt
- C215222
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001814Explore in graph →
Clinical trials
2,046 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07711509 | Autologous Fecal Microbiota Transplantation for Anal Function Recovery After Ileostomy Reversal in Rectal Cancer | active not recruiting | N/A | 35 | Peking University People's HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03712566 | Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy(MASST) | active not recruiting | — | 39 | University Health Network, TorontoOTHER | 1 | Jul 14, 2026 |
| clinicaltrials |
| NCT05400122 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | suspended | Phase 1 | 12 | David WaldOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06205485 | Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer(NEO-RT) | recruiting | Phase 3 | 250 | Canadian Cancer Trials GroupNETWORK | 2 | Jul 14, 2026 | clinicaltrials |
| NCT06340646 | Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS) | recruiting | N/A | 990 | Washington University School of MedicineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04815694 | THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy(THUNDER2) | recruiting | N/A | 179 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05538195 | Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors | completed | Phase 1 / Phase 2 | 17 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07687875 | Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer(OV-PRIME-R) | recruiting | Phase 1 | 20 | Henry SmithOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07695519 | SCARLET - Italian proSpeCtionAl obseRvationaL multicEntre Study on Treatment for recTal pT1 Cancer(SCARLET) | not yet recruiting | — | 196 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07696169 | Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers | not yet recruiting | — | 1,000 | Shenzhen Third People's HospitalOTHER | 0 | Jul 10, 2026 | clinicaltrials |
| NCT05054959 | Consolidation Versus Induction Chemotherapy in Total Neoadjuvant Therapy of Rectal Cancer With High Risk for Recurrence(ICONA) | active not recruiting | Phase 2 | 62 | Institute of Oncology LjubljanaOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07691489 | A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer | not yet recruiting | Phase 2 | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07692152 | Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma | recruiting | Phase 3 | 350 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT03603808 | VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions | completed | Phase 2 | 44 | AIDS Malignancy ConsortiumNETWORK | 2 | Jul 8, 2026 | clinicaltrials |
| NCT03879109 | Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer(GRECCAR15) | completed | Phase 3 | 58 | University Hospital, BordeauxOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT05308446 | Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | active not recruiting | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 2 | Jul 8, 2026 | clinicaltrials |
| NCT05628194 | ASSESSING THE GAY MALE EXPERIENCE WITH ANAL CANCER PREVENTION STRATEGIES | active not recruiting | — | 92 | University of MinnesotaOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06933251 | PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer | active not recruiting | Phase 2 | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT02816879 | Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men | active not recruiting | N/A | 415 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT03345563 | Project HERO: Health Empowerment & Recovery Outcomes(HERO) | completed | N/A | 113 | Rutgers, The State University of New JerseyOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05507112 | TIME in Immunotherapy Combined With nCRT for Rectal Cancer(TIMENT-R) | active not recruiting | Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07688135 | Quicksilver II Pilot Study | not yet recruiting | N/A | 18 | Mount Sinai Hospital, CanadaOTHER | 0 | Jul 7, 2026 | clinicaltrials |
| NCT04184973 | Efficacy and Safety of the CG-100 Intraluminal Bypass Device | recruiting | N/A | 250 | Colospan Ltd.INDUSTRY | 5 | Jul 6, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07680088 | Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer | not yet recruiting | Phase 2 | 17 | University of Texas Southwestern Medical CenterOTHER | 0 | Jul 2, 2026 | clinicaltrials |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer | terminated | Phase 2 | 17 | University of Southern CaliforniaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04643366 | Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer | recruiting | Phase 2 | 64 | Virginia Commonwealth UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05629442 | ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer | not yet recruiting | — | 60 | Massachusetts General HospitalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06364384 | Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma | recruiting | Phase 2 | 20 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07549399 | SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC(CRITⅡ) | recruiting | Phase 3 | 204 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07595874 | Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3(NEST3) | recruiting | Phase 2 | 100 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03051464 | Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery(MORPHEUS) | recruiting | Phase 2 / Phase 3 | 131 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 2 | Jun 30, 2026 | clinicaltrials |
| NCT04287868 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06507371 | Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer(mRCAT-III) | active not recruiting | Phase 3 | 170 | Sir Run Run Shaw HospitalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT02945566 | Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?(STAR-TREC) | active not recruiting | Phase 2 / Phase 3 | 380 | University of BirminghamOTHER | 5 | Jun 29, 2026 | clinicaltrials |
| NCT04926324 | A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers | terminated | Phase 1 | 3 | University of IowaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06780787 | FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery | recruiting | Phase 2 | 26 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07668284 | COQ10 and Vitamin E for Off-Target Radiation Toxicity | not yet recruiting | Phase 1 / Phase 2 | 200 | University of NebraskaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07669220 | A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)(STAR) | recruiting | Phase 2 | 76 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07669298 | Active Surveillance vs Adjuvant Chemoradiotherapy for Locally Resected Intermediate-Risk T1 Rectal Cancer(T-REX) | recruiting | N/A | 480 | Medical University of GdanskOTHER | 2 | Jun 25, 2026 | clinicaltrials |
| NCT06884670 | Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study | completed | Phase 2 | 130 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03179540 | Non-operative Management for Locally Advanced Rectal Cancer(NOM) | recruiting | N/A | 90 | Mount Sinai Hospital, CanadaOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04323722 | Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer(MESORECT-VV) | completed | N/A | 53 | Institut Cancerologie de l'OuestOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04929028 | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05772481 | Interest of PET-MRI in the Evaluation of the Response After Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma(TEPIREC) | recruiting | — | 50 | Centre Paul StraussOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07209787 | SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak | recruiting | Phase 4 | 966 | Beijing Chao Yang HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07596290 | Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC(RADICAL) | not yet recruiting | Phase 2 / Phase 3 | 342 | Beijing Friendship HospitalOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT05038254 | Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events | active not recruiting | N/A | 750 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 17, 2026source: clinicaltrials